Clearside Biomedical Inc
CLM
Company Profile
Business description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Contact
900 North Point Parkway
Suite 200
AlpharettaGA30005
USAT: +1 678 270-3631
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,890.80 | 74.40 | 0.84% |
| CAC 40 | 7,817.33 | 95.24 | 1.23% |
| DAX 40 | 24,267.71 | 258.33 | 1.08% |
| Dow JONES (US) | 44,386.34 | 131.56 | 0.30% |
| FTSE 100 | 8,970.64 | 44.09 | 0.49% |
| HKSE | 24,498.95 | 18.81 | -0.08% |
| NASDAQ | 20,755.84 | 25.35 | 0.12% |
| Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
| NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
| S&P 500 | 6,268.56 | 4.86 | 0.08% |
| S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
| SSE Composite Index | 3,516.83 | 13.05 | 0.37% |